SAVE THE DATE - 2022 Ovarian Cancer Midwest Focus Conference
ABOUT OUR CONFERENCE
The 2022 Ovarian Cancer Midwest Focus (OCMF) Conference will be both an in-person and a virtual conference that will include live streamed discussion rounds with national and international speakers, short talks based on abstracts, and group discussions. Topics will include Early Detection, Immunotherapy, Novel Therapeutics, Metabolism, Preclinical Models of Ovarian Cancer, Personalized Medicine, Microenvironment, Epigenetics, PARP Inhibitors, Chemoresistance, Combination Therapy, Clinical Studies, Technology Commercialization, and Career Development (lunch and learn).
REGISTER
OCMF AT-A-GLANCE
The Symposium will begin virtually and in-person on Thursday morning. The conference is single-track (no concurrent sessions) to give all attendees the opportunity to hear all presentations and discussions. Each day will feature Keynote Speakers, Flash Talks, and Lunch and Learn Presentations.
ORAL PRESENTATIONS BASED ON ABSTRACTS
Oral presentations are 5 minutes in length and are given in a plenary format to an interdisciplinary audience of approximately 100 attendees. Hence, the content should be interesting to a diverse audience and clearly focused to deliver two or three key points.
This conference aims to provide a collaborative environment which will allow an interdisciplinary approach to ovarian cancer research; a broad range of topics will be covered that address topic areas related to ovarian cancer research, including:
The deadline for oral presentation proposals is October 14, 2022.
Submission a session proposal for oral presentation abstract.
Agenda
Session I: Microenvironment
Moderators: Ronny Drapkin, M.D., Ph.D. - University of Pennsylvania - Perelman School of Medicine
Andrew Godwin, Ph.D. - University of Kansas Medical Center - Kansas Institute for Precision Medicine
Thursday 11/10/22 - AM
| Last Name | First Name | Time | |
| 7:15 - 8:00 | BREAKFAST | ||
| 8:00 - 8:05 | OPENING REMARKS - Melissa Geller, MD, MS Director of the Division of Gynecologic Oncology | ||
| 8:05 - 8:15 | Welcome Videos | ||
| Burdette, Ph.D. | Joanna | 8:15 - 8:45 | "PAX8 as a target in high grade serous ovarian cancer" KEYNOTE SPEAKER |
| Introduction by Dr. Godwin | |||
| Coffman, M.D., Ph.D, | Lan | 8:45 - 9:05 | “Mesenchymal stem cells: architects of the ovarian cancer stromal microenvironment” |
| Lou, M.D., Ph.D. | Emil | 9:05 - 9:35 | "Cellular networking via tunneling nanotubes in ovarian cancer" |
| Santagata, M.D., Ph.D. | Sandro | 9:35 - 10:05 | “Cyclic Immunofluorescence as a geospatial approach to ovarian cancer” |
| 10:05 - 10:15 | BREAK | ||
| Stack, Ph.D. | M. Sharon | 10:15 - 10:35 | "Mechanobiology in ovarian cancer" |
| Vermeer, Ph.D. | Paola | 10:35 - 10:55 | "Tumor Innervation in ovarian cancer" |
| 10:55 - 11:05 | Q&A | ||
| 11:05 - 11:45 | Flash Talks from Abstracts (5mins + 5 mins) | ||
| 11:45 - 11:55 | Exhibitor/Sponsor Presentations and Q&A | ||
| 11:55 - 12:05 | BREAK-LUNCH BEGINS | ||
| 12:05 - 12:45 | Exhibitor/Sponsor Presentations and Q&A | ||
| 12:45 - 1:45 | Poster Session |
Session II: Ovarian Cancer Stem Cells
Moderator: Ilana Chefetz, Ph.D. - The Hormel Institute, University of Minnesota
Thursday 11/10/22 - PM
| Last Name | First Name | Time | |
| Buchanovich, M.D., Ph.D. | Ron | 1:45 - 2:05 | "Targeting quiescent cancer cells to overcome chemotherapy resistance" |
| DiFeo, Ph.D. | Analisa | 2:05 - 2:25 | "miRNA and ovarian cancer stem cells" |
| Matei, MD | Daniela | 2:25 - 2:45 | "Unfolded protein response pathway and ovarian cancer stem cells" |
| 2:45 - 2:55 | Q&A | ||
| 2:55 - 3:05 | BREAK | ||
| Rueda, Ph.D. | Bo R. | 3:05 - 3:25 | "Post-treatment enrichment of ovarian cancer stem cells" |
| Robson, Ph.D. | Tracy | 3:25 - 3:45 |
"Harnessing the anti-angiogenic and anti-cancer stem cell properties of FKBPL; discovery to clinic in ovarian cancer" |
| Bowtell, Ph.D. | David | 3:45 - 4:15 | "Women who beat the odds: Molecular analysis of long-term high grade serous ovarian cancer survivors" - KEYNOTE SPEAKER |
| 4:15 - 4:30 | Q&A | ||
| 4:30 - 4:35 | CLOSING REMARKS - Ilana Chefetz, Ph.D. | ||
| 5:00 - 6:00 | Social / Cash Bar | ||
| 6:00 | DINNER - Heavy apps, cash bar at The Graduate Hotel | ||
| 7:00 | TopGolf, AirHockey, etc tournament at The Graduate Hotel |
Session I: Tumor Microenvironment 2 and Aging
Moderator: Martina Bazzaro, Ph.D.
Friday 11/11/22 - AM
| Last Name | First Name | Time | |
| 7:15 - 8:00 | BREAKFAST - Location TBD | ||
| 8:00 - 8:05 | OPENING REMARKS – Martina Bazzaro, Ph.D. | ||
| Hui, Ph.D. | Shen | 8:10 - 8:30 | "The epigenome of tubal precursors and ovarian cancer” |
| Chien, Ph.D. | Shen | 8:30 - 8:50 | "Adaptive responses contributing to treatment resistance in ovarian cancer." |
| Cho, M.D. | Kathleen | 8:50 - 9:10 | “Modeling ovarian cancer in post-menopausal setting” |
| 9:10 - 9:20 | Q&A | ||
| 9:20 - 9:30 | BREAK | ||
| Lawrenson, Ph.D. | Kate | 9:30 - 9:50 |
"Rewiring of Transcriptional Circuits During Ovarian Cancer Development" |
| Pathania, Ph.D. | Shailja | 9:50 - 10:10 | “Why the fallopian tube?” |
| Uhlin, Ph.D. | Michael | 10:10 - 10:30 | "Gamma delta T cells in ovarian cancer" |
| 10:30 - 10:40 | Q&A | ||
| 10:40 - 10:50 | BREAK | ||
| 10:50 - 11:30 | Flash Talks from Abstracts (5 min + 5 mins) | ||
| 11:30 - 11:40 | Q&A | ||
| 11:40 - 12:00 | BREAK-LUNCH BEGINS | ||
| 12:00 - 12:40 | Exhibitor/Sponsor Presentations/Poster Session | ||
| 12:40 - 12:50 | BREAK |
Session 2: Translating innovations to the clinic
Moderator: Gottfried E. Konecny, M.D., University of California - Los Angeles
Friday 11/11/22 - PM
| Last Name | First Name | Time | |
| 1:00 - 1:20 | TBD | ||
| Fuh, M.D., Ph.D. | Katherine | 1:20 - 1:40 | “Targeting AXL as a novel strategy” |
| Dorigo, M.D., Ph.D. | Oliver | 1:40 - 2:00 | “Immunotherapy of Ovarian Cancer" |
| 2:00 - 2:10 | Q&A | ||
| 2:10 - 2:20 | BREAK | ||
| Durocher, Ph.D. | Daniel | 2:20 - 2:40 | "Identification of PKMYT1 as a vulnerability in CCNE1-amplified cancers" |
| Christie, Ph.D. | Liz | 2:40 - 3:00 | TBD |
| 3:00 - 3:10 | Q&A | ||
| Konecny | Gottfried | 3:10 | CLOSING REMARKS |
